Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Simple Summary The abundance and the dynamic of the studies on NSCLC require
frequent summaries of the current achievements in the field. In our review, we aimed to …

The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been
evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver …

Recent changes in lung cancer care, including new approvals in first line and the
introduction of high-throughput molecular technologies in routine testing led us to question …

The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …

Abstract Purpose of Review Lung cancer remains the leading cause of cancer-related
mortality worldwide. Genetic and molecular profiling of non-small cell lung cancer (NSCLC) …

For patients with advanced stage non-small cell lung cancer (NSCLC), treatment strategies
have changed significantly due to the introduction of targeted therapies and immunotherapy …

The increasing number of approved drugs along with next generation sequencing (NGS)
technologies look out as potential revolution of biomolecular characterization of non-small …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Simple Summary In the field of non-small cell lung cancer (NSCLC), there have been
significant advancements in genomic data and bioinformatics tools, which have improved …